Compare Abeona Therapeutics Inc (ABEO) vs Duolingo Inc (DUOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Duolingo Inc — how do they compare? Abeona Therapeutics Inc trades at $7.46 (market cap $421.19M), while Duolingo Inc trades at $135 (market cap $6.34B). The key difference: Duolingo Inc is far larger — about 15.1× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | DUOL | |
|---|---|---|
Market Cap | $421.19M | $6.34B |
Sector | Health | Technology |
52-Week High | $7.45 | $369.19 |
52-Week Low | $4.17 | $90.03 |
Enterprise Value | $276.10M | $5.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Duolingo (DUOL) trades at $132.75, down 3.24% over 24 hours, with a bullish technical outlook from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.66 versus $0.604 expected, driven by 23% daily active user growth. Revenue reached $1.04 billion in 2025, with net income surging to $414 million, though Q3 2026 revenue guidance fell short of expectations, causing recent stock pressure.
The investment outlook is mixed: robust user growth and profitability metrics like a 35.87% net margin support upside, but decelerating bookings growth and margin pressures from AI investments pose risks. Analysts show cautious optimism with a $121 consensus target, highlighting the stock's sensitivity to monetization trends amid competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Duolingo Inc
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →
